Critical Contrast: Alternate Health (OTCMKTS:AHGIF) vs. Fulgent Genetics (NASDAQ:FLGT)

Fulgent Genetics (NASDAQ:FLGT) and Alternate Health (OTCMKTS:AHGIF) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Fulgent Genetics and Alternate Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1	1	2	1	2.60
Alternate Health	0	0	0	0	0.00

Fulgent Genetics currently has a consensus target price of $32.00, indicating a potential upside of 22.14%. Given Fulgent Genetics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Fulgent Genetics is more favorable than Alternate Health.

Earnings & Valuation

This table compares Fulgent Genetics and Alternate Health”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$283.47 million	2.86	-$42.71 million	($1.39)	-18.85
Alternate Health	N/A	N/A	N/A	N/A	N/A

Alternate Health has lower revenue, but higher earnings than Fulgent Genetics.

Profitability

This table compares Fulgent Genetics and Alternate Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-13.62%	-2.55%	-2.36%
Alternate Health	N/A	N/A	N/A

Institutional & Insider Ownership

48.1% of Fulgent Genetics shares are owned by institutional investors. 31.8% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Fulgent Genetics beats Alternate Health on 7 of the 10 factors compared between the two stocks.

About Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

About Alternate Health

Alternate Health Corp., a diversified healthcare company, provides cloud based software solutions in Canada. It offers medical practice and controlled substance management software, blood analysis and toxicology labs, clinical research, continuing education programs, nutraceutical products, and security and control services to the medical cannabis industry. The company is headquartered in Toronto, Canada.